ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Eosinophilic Leukemia
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Erythroleukemia (M6a)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: eltrombopag olamine
Procedure: standard follow-up care

First Posted Date: 2012-03-09

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 10

Registration Number: NCT01550185

Locations: 🇺🇸
Emory University, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer
Colorectal Tumors
Colorectal Carcinoma
Neoplasms, Colorectal

Interventions: Drug: Chemokin Modulatory Regimen (10 MU/m2)
Drug: Chemokin Modulatory Regimen (5 MU/m2)
Drug: Chemokin Modulatory Regimen (20 MU/m2)

First Posted Date: 2012-03-06

Last Posted Date: 2023-10-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT01545141

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: PI3K inhibitor BKM120
Drug: docetaxel
Other: pharmacological study
Other: questionnaire administration
Other: laboratory biomarker analysis

First Posted Date: 2012-02-28

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 38

Registration Number: NCT01540253

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Phase 2

Terminated

Conditions: Waldenström Macroglobulinemia

Interventions: Biological: ofatumumab
Drug: bortezomib
Other: laboratory biomarker analysis

First Posted Date: 2012-02-20

Last Posted Date: 2016-06-10

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01536067

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Weill Cornell Medical College, New York, New York, United States

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IIA Fallopian Tube Cancer
Stage IIA Ovarian Epithelial Cancer
Stage IIA Primary Peritoneal Cavity Cancer
Stage IIB Fallopian Tube Cancer
Stage IIB Ovarian Epithelial Cancer
Stage IIB Primary Peritoneal Cavity Cancer
Stage IIC Fallopian Tube Cancer

Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Drug: sirolimus
Other: laboratory biomarker analysis
Biological: sargramostim

First Posted Date: 2012-02-20

Last Posted Date: 2020-03-27

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 7

Registration Number: NCT01536054

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Metastatic Intraocular Melanoma
Recurrent Intraocular Melanoma
Stage IIIA Intraocular Melanoma
Stage IIIB Intraocular Melanoma
Stage IIIC Intraocular Melanoma
Stage IV Intraocular Melanoma
Stage IIIB Melanoma
Extraocular Extension Melanoma
Recurrent Melanoma
Stage IIIC Melanoma

Interventions: Drug: axitinib
Other: laboratory biomarker analysis

First Posted Date: 2012-02-16

Last Posted Date: 2018-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 25

Registration Number: NCT01533948

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression

Completed

Conditions: Oral Cancer

First Posted Date: 2012-02-13

Last Posted Date: 2023-04-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 240

Registration Number: NCT01531881

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia in Remission
Childhood Acute Myeloid Leukemia in Remission
Childhood Chronic Myelogenous Leukemia
Childhood Grade III Lymphomatoid Granulomatosis
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Drug: fludarabine phosphate
Drug: melphalan
Radiation: total-body irradiation
Drug: tacrolimus
Drug: mycophenolate mofetil
Drug: methotrexate
Other: laboratory biomarker analysis
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2012-02-09

Last Posted Date: 2019-09-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 94

Registration Number: NCT01529827

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Stage I Mantle Cell Lymphoma
Stage II Contiguous Mantle Cell Lymphoma
Stage II Non-Contiguous Mantle Cell Lymphoma
Stage III Mantle Cell Lymphoma
Stage IV Mantle Cell Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Biological: Ofatumumab
Drug: Vincristine Sulfate

First Posted Date: 2012-02-06

Last Posted Date: 2024-02-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 37

Registration Number: NCT01527149

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: entolimod
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2012-02-06

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 25

Registration Number: NCT01527136

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

AI-Powered Research

Premium Access

ROSWELL PARK CANCER INSTITUTE

Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Autofluorescence Detection of Oral Malignancies and Database and Biospecimen Collection to Identify Biomarkers of Head and Neck Tumor Progression

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery